CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 15:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

08 May 2024 15:15:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

30 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

16 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

18 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

12 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

12 Mar 2024 08:45:16 By NetDania Notify

NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

11 Mar 2024 11:16:48 By NetDania Notify

NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

08 Mar 2024 08:45:23 By NetDania Notify

NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

07 Mar 2024 08:45:03 By NetDania Notify

NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

06 Mar 2024 11:23:17 By NetDania Notify

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

29 Feb 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

07 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

14 Dec 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

13 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

08 Nov 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

07 Nov 2023 15:20:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

02 Nov 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

01 Nov 2023 06:05:00 By Nasdaq GlobeNewswire